Quick Answer
Exousia Bio, Inc. reported Total Revenue of $3.8 thousand for fiscal year 2025.
Exousia Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $3.8K -67.4% |
$11.5K | $0.00 | — |
| Net Income | $51.4K +299.2% |
-$25.8K +54.3% |
-$56.4K | — |
| Diluted EPS | $0.00 | $0.00 | $0.00 | — |
| Total Assets | $0.00 -100.0% |
$27.5K -25.9% |
$37.0K -31.4% |
$54.0K |
| Cash and Equivalents | — | — | $7.9K -22.3% |
$10.1K |
| Stockholders Equity | $0.00 +100.0% |
-$54.9K -88.7% |
-$29.1K | $0.00 |
| Operating Income | — | — | -$56.4K | — |
| Gross Profit | -$3.5K -291.0% |
$1.8K | $0.00 | — |
| Shares Outstanding | 7.78M +0.0% |
7.78M +0.0% |
7.78M +55.5% |
5.00M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | November 30, 2025 | $0.00 | — | — |
| Net Income | November 30, 2025 | -$19.1K | -123.8% | +40.0% |
| Diluted EPS | November 30, 2025 | $0.00 | -100.0% | — |
| Total Assets | November 30, 2025 | $22.05M | +88620.8% | — |
| Cash and Equivalents | August 31, 2023 | $1.3K | — | -83.2% |
| Stockholders Equity | November 30, 2025 | $21.79M | +87570.6% | +61802.6% |
| Operating Income | November 30, 2025 | -$237.0K | -3495.0% | -645.0% |
| Gross Profit | November 30, 2025 | -$62.1K | — | — |
| Shares Outstanding | November 30, 2025 | 70.00M | +800.1% | +800.1% |
- Exousia Bio, Inc. reported Total Revenue of $3.8 thousand for fiscal year 2025.
- Exousia Bio, Inc. showed a decrease of -67.4% in Total Revenue compared to the prior fiscal year.
- Exousia Bio, Inc. reported Net Income of $51.4 thousand for fiscal year 2025.
- Exousia Bio, Inc. showed an increase of +299.2% in Net Income compared to the prior fiscal year.
- Exousia Bio, Inc. reported Diluted EPS of $0.00 per share for fiscal year 2025.
- Exousia Bio, Inc. reported Total Assets of $0.00 for fiscal year 2025.
- Exousia Bio, Inc. showed a decrease of -100.0% in Total Assets compared to the prior fiscal year.
- Exousia Bio, Inc. reported Cash and Equivalents of $7.9 thousand for fiscal year 2023.
- Exousia Bio, Inc. showed a decrease of -22.3% in Cash and Equivalents compared to the prior fiscal year.
- Exousia Bio, Inc. reported Stockholders Equity of $0.00 for fiscal year 2025.
- Exousia Bio, Inc. showed an increase of +100.0% in Stockholders Equity compared to the prior fiscal year.
- Exousia Bio, Inc. reported Operating Income of -$56.4 thousand for fiscal year 2023.
- Exousia Bio, Inc. reported Gross Profit of -$3.5 thousand for fiscal year 2025.
- Exousia Bio, Inc. showed a decrease of -291.0% in Gross Profit compared to the prior fiscal year.
- Exousia Bio, Inc. reported Shares Outstanding of 7.78 million shares for fiscal year 2025.
- Exousia Bio, Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: